scholarly journals Assessment of patients with multiple sclerosis according to tests of the Multiple Sclerosis Functional Composite

2016 ◽  
Vol 29 (4) ◽  
pp. 677-684 ◽  
Author(s):  
Anelise Ineu Figueiredo ◽  
Carla Roberta Nunes Polachini ◽  
Ana Lucia Cervi Prado
Keyword(s):  
Multiple Sclerosis ◽  
Upper Limb ◽  
Healthy Subjects ◽  
Skewed Distribution ◽  
Control Group ◽  
Functional Composite ◽  
Multiple Sclerosis Functional Composite ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
Student’S T

Abstract Introduction: The Multiple Sclerosis Functional Composite (MSFC) is a scale that evaluates the functional and cognitive aspects of patients with multiple sclerosis (MS). Objective: To compare the performance of individuals with the relapsing-remitting form of MS (RRMS) with a group of healthy subjects using the MSFC. Methods: Twenty subjects were investigated in this study, consisting of 10 patients with clinical diagnosis of RRMS and 10 controls with similar gender and age to the group with the disease. The three tests that comprise the MSFC were used for the evaluation of gait, upper limb motor function and cognition (memory and processing speed). Student's t-test was used to assess data with normal distribution and data with skewed distribution were evaluated using the Mann-Whitney test. Results: The results showed that the patients with RRMS took longer to perform the locomotion test (6.91 ± 2.35) compared to the control group (5.16 ± 1.28). The MS group (22.06 ± 5.44) also showed greater difficulty in performing a task with the dominant upper limb compared to the healthy subjects (17.79 ± 2.96). No statistically significant difference was found between the groups in the performance of cognitive tasks (p = .65). Conclusion: The use of the MSFC tests proved valuable for measuring possible motor and cognitive impairments in patients with RRMS. Thus, it is suggested that this scale is adopted in clinical practice, improving therapies for the treatment of MS patients and thereby providing them a better quality of life.

Matrix metalloproteinases and their tissue inhibitors in relapsing remitting multiple sclerosis : Possible markers and treatment agents

2021 ◽  
Vol 74 (1-2) ◽  
pp. 50-56
Author(s):  
Arzu Sanli ◽  
Musa Ozturk ◽  
Aysun Soysal ◽  
Yasemin Doventas ◽  
Fulya Basoglu ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Matrix Metalloproteinases ◽  
Patient Group ◽  
Healthy Subjects ◽  
Early Period ◽  
Control Group ◽  
Tissue Inhibitors ◽  
Remission Period ◽  
Significant Difference ◽  
Relapsing Remitting

Matrix metalloproteinases (MMPs), which are synthesized by many cell groups and responsible for the destruction of matrix proteins, and endogen tissue inhibitors of MMPs (TIMPs) have a role in the pathogenesis of Multiple Sclerosis (MS) by affecting the blood-brain barrier. We aimed to investigate the role of MMPs and TIMPs in the immunopathogenesis and in the course of multiple sclerosis (MS). We enrolled 25 relapsing remitting MS patients, who had a definite MS diagnosis according to McDonald criteria and 25 healthy subjects similar for age and gender as control group. MMP-9- and TIMP-1 levels were measured twice in patient group (one time during an attack and one in remission) and once in healthy subjects. MMP-9- and TIMP-levels of patients during attack and remission period and MMP-9/TIMP-1 ratio were found significantly higher than in the control subjects. In patient group MMP-9 and TIMP-1 levels and MMP-9/TIMP-1 ratio during attacks were not significantly different than during remission period. However, when subdivided according to their number of attacks, patients with 2 attacks had significantly higher levels during attack period comparing to remission period (p<0.05); in case of patients with more than 2 attacks did not have a statistically significant difference in attack and remission periods. Matrix metalloproteinases are important actors in MS immunopathogenesis, particularly in the early period and inhibitor agents for these enzymes can be used as a treatment option.

Metabolic differences between multiple sclerosis subtypes measured by quantitative MR spectroscopy

2002 ◽  
Vol 8 (3) ◽  
pp. 200-206 ◽  
Author(s):  
J W Pan ◽  
P K Coyle ◽  
K Bashir ◽  
J N Whitaker ◽  
L B Krupp ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Neuronal Loss ◽  
Control Group ◽  
Periventricular White Matter ◽  
Quantitative Mr ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
White Matter Region ◽  
Metabolite Ratio ◽  
And Control

We used quantitative magnetic resonance (MR) spectroscopic imaging with T1-based image segmentation to evaluate the subtypes of multiple sclerosis (MS) (eight patients each group of relapsing-remitting [RR], secondary progressive [SP] and primary progressive [PP]). There was no significant difference in age between the PP group with the RR, SP or control group. We found that the metabolite ratio of choline/NA from the periventricular white matter region was not significantly different between the RR and SP groups. Using an ANOVA, the ratios of periventricular choline/NA or creatine/NA of these combined groups were significantly higher than the PP and control groups. Quantification of these data suggest that the major cause of the elevation of these parameters is due to an increase in choline and creatine in the RR group while NA is decreased in the SP group. Thus, early PP disease appears to be relatively intact with respect to neuronal loss.

No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing–remitting multiple sclerosis (the ARIANNA study)

2016 ◽  
Vol 22 (9) ◽  
pp. 1163-1173 ◽  
Author(s):  
Roberta Lanzillo ◽  
Mario Quarantelli ◽  
Carlo Pozzilli ◽  
Maria Trojano ◽  
Maria Pia Amato ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Brain Atrophy ◽  
Composite Score ◽  
Expanded Disability Status Scale ◽  
Functional Composite ◽  
Multiple Sclerosis Functional Composite ◽  
Disability Status ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Background: A previous phase 2 trial has suggested that statins might delay brain atrophy in secondary progressive multiple sclerosis. Objectives: The objective of this study was to evaluate the effect of atorvastatin add-on therapy on cerebral atrophy in relapsing–remitting multiple sclerosis. Methods: This randomised, placebo-controlled study compared atorvastatin 40 mg or placebo add-on therapy to interferon β1b for 24 months. Brain magnetic resonance imaging, multiple sclerosis functional composite score, Rao neuropsychological battery and expanded disability status scale were evaluated over 24 months. Results: A total of 154 patients were randomly assigned, 75 in the atorvastatin and 79 in the placebo arms, with a comparable drop-out rate (overall 23.4%). Brain atrophy over 2 years was not different in the two arms (−0.38% and −0.32% for the atorvastatin and placebo groups, respectively). Relapse rate, expanded disability status scale, multiple sclerosis functional composite score or cognitive changes were not different in the two arms. Patients withdrawing from the study had a higher number of relapses in the previous 2 years ( P=0.04) and a greater probability of relapsing within 12 months. Conclusions: Our results suggest that the combination of atorvastatin and interferon β1b is not justified in early relapsing–remitting multiple sclerosis and adds to the body of evidence indicating an absence of significant radiological and clinical benefit of statins in relapsing–remitting multiple sclerosis.

Possible association between multiple sclerosis and the human T cell leukemia virus (HTLV)-related endogenous element, HRES-I

1996 ◽  
Vol 2 (3) ◽  
pp. 133-136 ◽  
Author(s):  
HB Rasmussen ◽  
A Heltberg ◽  
K Christensen ◽  
J Clausen
Keyword(s):  
Multiple Sclerosis ◽  
Leukemia Virus ◽  
Endogenous Retrovirus ◽  
Control Group ◽  
Healthy Individuals ◽  
Cell Leukemia ◽  
Human T Cell ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
T Cell Leukemia Virus

In the present study we searched for an association between the human endogenous retroviral element HRES-I and multiple sclerosis (MS). Fragments of this endogenous retrovirus were amplified for subsequent examination by single strand conformational analysis. We did not find HRES-I markers exclusively linked with MS and only the two already known polymorphisms, which define three alleles of HRES-I, were detected. However, we found a significant difference in the distribution of these alleles between a group of 87 MS patients and a control group of 158 healthy individuals (P=0.014). There were no differences in the distribution of the HRES-I allelic forms between MS patients with a relapsing-remitting course and patients with chronic progressive MS. Our results provide evidence of an association between HRES-I and MS. Possible explanations for this are discussed.

scholarly journals Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis

2004 ◽  
Vol 10 (3) ◽  
pp. 281-283 ◽  
Author(s):  
A Petzold ◽  
D Brassat ◽  
P Mas ◽  
K Rejdak ◽  
G Keir ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Response ◽  
Healthy Subjects ◽  
Surrogate Marker ◽  
Control Group ◽  
Surrogate Markers ◽  
Resonance Imaging ◽  
Exact Test ◽  
Relapsing Remitting ◽  
Nitric Oxide Metabolites

Background: This study aimed to investigate if treatment response could retrospectively be related to inflammatory or axonal patho logy as measured by plasma surrogate markers. Methods: In this 1-year observational study 30 multiple sclerosis (MS) patients with relapsing-remitting disease were treated with intramuscular IFNb-1a or subcutaneous IFNb-1b. Responders and nonresponders were defined according to clinical and magnetic resonance imaging criteria. The control group consisted of 14 healthy subjects. Plasma levels of surrogate markers for inflammation (nitric oxide metabolites (NO x)), astrocytic activation (S100B) and axonal damage (NfHSMI35) were measured using standard assays. Results: There were 11 nonresponders and 19 responders to IFNb treatment. Median S100B levels were elevated in a higher proportion of treatment responders (63%, 42.9 pg/mL) compared to nonresponders (18%, 11.7 pg/mL, PB- 0.05, Fisher’s exact test) and controls (0%, 2 pg/mL, PB- 0.001). Levels of NO x were found to be more frequently elevated in nonresponders (72%, 39 mM) compared to healthy controls (0%, 37 mM, PB- 0.05). Levels of NfHSMI35 were more frequently elevated in responders (58%, 300 pg/mL, PB- 0.001) and nonresponders (72%, 500 pg/mL, PB- 0.001) compared to controls (0%, 4.5 pg/mL). Conclusion: Patients with relapsing-remitting MS who had surrogate marker supported evidence for astrocytic activation responded more frequently to treatment with IFNb.

Correlation between DJ-1 levels in the cerebrospinal fluid and the progression of disabilities in multiple sclerosis patients

2008 ◽  
Vol 14 (8) ◽  
pp. 1056-1060 ◽  
Author(s):  
M Hirotani ◽  
C Maita ◽  
M Niino ◽  
SM Iguchi-Ariga ◽  
S Hamada ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Healthy Subjects ◽  
Significant Positive Correlation ◽  
Healthy Controls ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
Multiple Sclerosis Patients

Objectives DJ-1 plays a key role in the anti-oxidative stress function. Increasing evidence supports the role of oxidative stress in the pathogenesis of multiple sclerosis (MS). The aim of this study was to investigate whether the DJ-1 levels were increased in patients with MS and to examine its association with the progression of MS. Methods Quantitative immunoblot assays were performed to evaluate the DJ-1 level in serum and cerebrospinal fluid (CSF) collected from relapsing–remitting patients with MS ( n = 29), disease controls subjects ( n = 14), and healthy subjects ( n = 44). Results No significant difference was observed in the serum DJ-1 level among the patients with MS, disease controls, and healthy controls. However, the CSF DJ-1 levels were significantly higher in the patients with MS than in the disease control subjects ( P < 0.0001). A significant positive correlation was also found between the CSF DJ-1 levels and the Multiple Sclerosis Severity Score ( P < 0.005, r = 0.501). Conclusions These results show that the CSF DJ-1 levels are significantly increased in the CSF of patients with MS and that the CSF DJ-1 levels may be associated with the disease progression of MS. Therefore, DJ-1 possibly plays an important role in the pathogenesis of MS.

scholarly journals Longitudinal analysis of verbal episodic memory in patients with relapsing-remitting multiple sclerosis

2018 ◽  
Vol 76 (5) ◽  
pp. 302-309
Author(s):  
Izadora Nogueira Fonte Boa ◽  
Carolina de Medeiros Rimkus ◽  
Kenia Repiso Campanholo ◽  
Samira Luisa Apóstolos Pereira ◽  
Thiago de Faria Junqueira ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Episodic Memory ◽  
Statistical Difference ◽  
Control Group ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
Neuropsychological Assessments ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Verbal Episodic Memory

ABSTRACT Objective: A 4.5-year follow-up study was conducted to characterize baseline verbal episodic memory (VEM) and its behavior and to assess the effects of relapsing-remitting multiple sclerosis (RRMS) on this domain. Methods: Twenty-nine patients with RRMS underwent two neuropsychological assessments performed an average of 4.5 years apart. Twenty-six control participants underwent a single neuropsychological assessment. A significance level of p < 0.005 was adopted to denote a significant difference between the groups on the Mann Whitney and Wilcoxon paired statistical analyses. Results: No statistical difference was found in the results of the VEM tests between the first and second neuropsychological assessments of the patients. However, a statistical difference was evident between the patient and control groups in the results of the VEM tests. Conclusion: The patient group showed changes in the VEM relative to the control group. After approximately 4.5 years of disease, the patient performance on the VEM stabilized or improved.

Olfactory Dysfunction and Cognition in Radiologically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis

2021 ◽  
pp. 1-8
Author(s):  
Ozge Arici Duz ◽  
Ozlem Saatci ◽  
Ece Zeynep Karakulak ◽  
Erkingul Birday ◽  
Lutfu Hanoglu
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Functions ◽  
Demyelinating Disease ◽  
Short Form ◽  
Depression Scale ◽  
Olfactory Dysfunction ◽  
Control Group ◽  
Radiologically Isolated Syndrome ◽  
Significant Difference ◽  
Relapsing Remitting

<b><i>Background:</i></b> Multiple Sclerosis (MS) is a neuroinflammatory, neurodegenerative, demyelinating disease that causes cognitive, olfactory, and other neurological dysfunctions. Radiologically Isolated Syndrome (RIS), in which only radiological findings are monitored, is accepted as the preclinical stage of demyelinating disease and is considered an important period for disease pathology. Therefore, in this study, we aimed to evaluate the olfactory and cognitive functions and their clinical correlation in RIS and Relapsing-Remitting MS (RRMS) patients and a healthy control group. <b><i>Methods:</i></b> Our study included 10 RRMS patients, 10 RIS patients, and 10 healthy controls. We conducted an olfactor evaluation via the “Sniffin’ Sticks” test. The subjects underwent a neuropsychometric test battery to evaluate cognitive functions, including memory, visuospatial, and executive functions. Depression was evaluated using the Beck depression scale. Fatigue and daily life activity were evaluated using the Fatigue Severity Scale (FSS) and the 36-Item Short Form Survey (SF-36), respectively. Disability assessment was done with the Expanded Disability Status Scale (EDSS). <b><i>Results:</i></b> RRMS and RIS patients’ olfactory test scores were significantly different from those in the control group (<i>p</i> &#x3c; 0.05). There was a significant difference between the odor threshold scores of patients in the RRMS and RIS groups. There was a significant correlation between memory-oriented cognitive tests and olfactory tests in the RRMS and RIS groups. <b><i>Conclusion:</i></b> Olfactory dysfunction can be seen in RIS patients, like in RRMS patients. Cognitive and olfactory dysfunction may be together a sign of degeneration in demyelinating diseases.

scholarly journals Prevalence of temporomandibular disorders symptoms in patients with multiple sclerosis

2014 ◽  
Vol 72 (6) ◽  
pp. 422-425 ◽  
Author(s):  
Lucas S. C. Carvalho ◽  
André P. C. Matta ◽  
Osvaldo J. M. Nascimento ◽  
Antônio S. Guimarães ◽  
Luciane R. Rodrigues
Keyword(s):  
Multiple Sclerosis ◽  
Temporomandibular Disorders ◽  
Control Group ◽  
European Academy ◽  
Gender And Age ◽  
Significant Difference ◽  
Disability Status ◽  
Relapsing Remitting ◽  
Age Range ◽  
The Relationship

The aim of the present study was to assess the prevalence of symptoms of temporomandibular disorders (TMD) in patients with the relapsing-remitting form of multiple sclerosis (MS), the relationship between TMD and the severity of MS, and the presence of TMD symptoms in the evaluated groups. Sixty individuals were evaluated: 30 patients diagnosed with relapsing-remitting MS and 30 control individuals matched for gender and age range with no neurologic pathology. In order to investigate the TMD symptoms, the questionnaires of the EACD (European Academy of Craniomandibular Disorders) and the RDC/TMD (Research Diagnostic Criteria for Temporomandibular Disorders), both validated for TMD research, were administered. To assess the extent of disability produced by MS, the Expanded Disability Status Scale (EDSS) was used. The prevalence of TMD symptoms in patients with MS was 56.7% versus 16.7% for the control group, with a statistically significant difference between the groups (p=0.0016). No correlation was found between the severity of MS and the prevalence of TMD symptoms (Fisher's test, p=1.0).

scholarly journals Relationship between Expanded Disability Status Scale scores and the presence of temporomandibular disorders in patients with multiple sclerosis

2018 ◽  
Vol 12 (01) ◽  
pp. 144-148 ◽  
Author(s):  
Lucas Senra Correa Carvalho ◽  
Osvaldo José Moreira Nascimento ◽  
Luciane Lacerda Franco Rocha Rodrigues ◽  
Andre Palma Da Cunha Matta
Keyword(s):  
Multiple Sclerosis ◽  
Temporomandibular Disorders ◽  
Control Group ◽  
Expanded Disability Status Scale ◽  
Exact Test ◽  
Disability Status ◽  
Relapsing Remitting ◽  
Scale Scores ◽  
Axis I ◽  
Relapsing Remitting Multiple Sclerosis

ABSTRACTObjectives: The objectives of this study were to assess the prevalence of temporomandibular disorders (TMDs) in patients with relapsing-remitting multiple sclerosis (MS) and to investigate whether an association exists between the presence of TMD symptoms and the degree of MS-related disability. Materials and Methods: In all, 120 individuals were evaluated: 60 patients with a diagnosis of relapsing-remitting MS and 60 age- and sex-matched controls without neurological impairments. A questionnaire recommended by the European Academy of Craniomandibular Disorders for the assessment of TMD symptoms was administered. For those who answered affirmatively to at least one of the questions, the RDC/TMD Axis I instrument was used for a possible classification of TMD subtypes. The Expanded Disability Status Scale (EDSS) was the measure of the degree of MS-related disability. Statistical Analysis Used: Fisher’s exact test was used to analyze the data. ANOVA was used to detect significant differences between means and to assess whether the factors influenced any of the dependent variables by comparing means from the different groups. Results: The prevalence of TMD symptoms in patients with MS was 61.7% versus 18.3% in the control group (CG). A diagnosis of TMD was established for 36.7% in the MS group and 3.3% in the CG (P = 0.0001). There were statistically significant differences between degrees of MS-related disability and the prevalence of TMD (P = 0.0288). Conclusions: The prevalence of both TMD and TMD symptoms was significantly greater in the MS group. EDSS scores and TMD prevalence rates were inversely related.

Sign in / Sign up

Export Citation Format

Share Document